Post by marriott on Dec 28, 2023 22:19:21 GMT
Nov 28, 2023 - Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization - Closed 5.73
Nov 29, 2023 - Novavax’s Updated COVID-19 Vaccine Receives Emergency Use Authorization in the Republic of Korea - Closed 5.59
Dec 5, 2023 - Novavax's Updated COVID-19 Vaccine Now Authorized in Canada - Closed 5.59
Dec 8, 2023 - Rising U.S. and EU COVID-19 Cases and Hospitalization Rates and the Need for COVID-19 Vaccination - Closed 5.57
Dec 11, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available in Austria - Closed 5.57
Dec 11, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available in Germany - Closed 5.57
Dec 11, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available as Only Option in Poland - Closed 5.57
Dec 14, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available in Italy - Closed 5.69
Dec 14, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available in Sweden - Closed 5.69
Dec 18, 2023 - Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan - Closed 5.16
Dec 19, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available in Canada - Closed 5.23
Dec 21, 2023 – R21/Matrix-M™ Malaria Vaccine Granted Prequalification by World Health Organization - Closed 4.94
So over a month with seemingly positive developments the share price declined from 5.73 to 4.94 - 14 percent decline.
Why? - Because the road to real earnings ( other than grants ) cannot be easily projected moving forward.
However, there are several catalysts that may help to move the share price upward during 2024:
- A potential “ short” squeeze given the short interest accounts for about half of the floating shares..
- A Management that provides solid guidance while buying Novavax shares in the open market.
- A clear structure regarding Praha and global production capabilities
- GAVI, GAVI, GAVI – reasonable resolution to Novavax’s bottom line would be a big catalyst going forward
- The going “ concern issue ”. Watch the actions of institutional investors during 2024.
I believe Novavax will need to raise more capital. Whether they decide to dilute shareholder equity or accrue more debt, the company must prvide clear and concise guidance as to how the additional capital will result in future earnings.
I am still a shareholder in Novavax but my patience on the pathway to the realization of true profits is getting shorter!
And, may you shareholders and your loved ones have a healthy and personally fulfilling New Year!
Nov 29, 2023 - Novavax’s Updated COVID-19 Vaccine Receives Emergency Use Authorization in the Republic of Korea - Closed 5.59
Dec 5, 2023 - Novavax's Updated COVID-19 Vaccine Now Authorized in Canada - Closed 5.59
Dec 8, 2023 - Rising U.S. and EU COVID-19 Cases and Hospitalization Rates and the Need for COVID-19 Vaccination - Closed 5.57
Dec 11, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available in Austria - Closed 5.57
Dec 11, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available in Germany - Closed 5.57
Dec 11, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available as Only Option in Poland - Closed 5.57
Dec 14, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available in Italy - Closed 5.69
Dec 14, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available in Sweden - Closed 5.69
Dec 18, 2023 - Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan - Closed 5.16
Dec 19, 2023 - Novavax’s Updated COVID-19 Vaccine Now Available in Canada - Closed 5.23
Dec 21, 2023 – R21/Matrix-M™ Malaria Vaccine Granted Prequalification by World Health Organization - Closed 4.94
So over a month with seemingly positive developments the share price declined from 5.73 to 4.94 - 14 percent decline.
Why? - Because the road to real earnings ( other than grants ) cannot be easily projected moving forward.
However, there are several catalysts that may help to move the share price upward during 2024:
- A potential “ short” squeeze given the short interest accounts for about half of the floating shares..
- A Management that provides solid guidance while buying Novavax shares in the open market.
- A clear structure regarding Praha and global production capabilities
- GAVI, GAVI, GAVI – reasonable resolution to Novavax’s bottom line would be a big catalyst going forward
- The going “ concern issue ”. Watch the actions of institutional investors during 2024.
I believe Novavax will need to raise more capital. Whether they decide to dilute shareholder equity or accrue more debt, the company must prvide clear and concise guidance as to how the additional capital will result in future earnings.
I am still a shareholder in Novavax but my patience on the pathway to the realization of true profits is getting shorter!
And, may you shareholders and your loved ones have a healthy and personally fulfilling New Year!